Profile: AbbVie Inc (ABBV.K)
23 Feb 2017
AbbVie Inc. (AbbVie), incorporated on April 10, 2012, is a research-based biopharmaceutical company. The Company develops and markets therapies that address a range of diseases. The Company operates in pharmaceutical products segment. The Company's products are focused on treating conditions, such as chronic autoimmune diseases, in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson's disease; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, as well as other serious health conditions. AbbVie also has a pipeline of new medicines, including over 50 compounds or indications in clinical development across medical specialties, such as immunology, virology/liver disease, oncology, neurological diseases and women's health. The Company's product portfolio includes HUMIRA, IMBRUVICA, HCV products, additional virology products, metabolics/hormones products, endocrinology products and other products.
HUMIRA is a biologic therapy administered as a subcutaneous injection. HUMIRA is approved to treat rheumatoid arthritis (moderate to severe), psoriatic arthritis, ankylosing spondylitis, crohn's disease (moderate to severe), plaque psoriasis (moderate to severe), juvenile idiopathic arthritis, ulcerative colitis (moderate to severe), axial spondyloarthropathy, pediatric crohn's disease (severe), hidradenitis suppurativa and pediatric enthesitis-related arthritis in the United States and in the European Union. HUMIRA is approved in over 60 other markets, including Japan, China, Brazil and Australia. AbbVie is conducting research to expand the indications for HUMIRA, including in the fields of rheumatology, gastroenterology (pediatric ulcerative colitis) and ophthalmology (uveitis).
IMBRUVICA (ibrutinib) is a first-in-class, oral, once-daily therapy that inhibits a protein called Bruton's tyrosine kinase (BTK). IMBRUVICA is approved for the treatment of patients with chronic lymphocytic leukemia (CLL) who have received approximately one prior therapy, CLL patients who have del 17p and patients with Waldenstrom's macroglobulinemia. IMBRUVICA is also approved for the treatment of patients with mantle cell lymphoma (MCL) who have received approximately one prior therapy.
Hepatitis C products
VIEKIRA PAK ((ombitsavir, paritaprevir, and ritonavir tablets, and dasabuvir tablets) is an all-oral, short-course, interferon-free therapy, with or without ribavirin, for the treatment of adult patients with genotype 1 chronic HCV, including patients with compensated cirrhosis. In Europe, AbbVie's HCV treatment is marketed as VIEKIRAX + EXVIERA and is approved for use in patients with genotype 1 and genotype 4 HCV.
Additional Virology products
AbbVie's additional virology products include Kaletra and Norvir for the treatment of HIV infection and Synagis for the prevention of respiratory syncytial virus (RSV) infection in high risk infants. Kaletra (lopinavir/ritonavir), which is also marketed as Aluvia, is a prescription anti-HIV-1 medicine that contains two protease inhibitors: lopinavir and ritonavir. Kaletra is used with other anti-HIV-1 medications as a treatment that maintains viral suppression in people with HIV-1. Norvir (ritonavir) is a protease inhibitor that is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection. Synagis (palivizumab) is a product marketed by the Company outside of the United States that protects at-risk infants from respiratory disease caused by RSV.
Metabolics/Hormones products target a range of conditions, including testosterone deficiency, exocrine pancreatic insufficiency and hypothyroidism. These products include AndroGel, which is a testosterone replacement therapy for males diagnosed with symptomatic low testosterone that is available in two strengths: 1% and 1.62%; Creon, a pancreatic enzyme therapy for exocrine pancreatic insufficiency, a condition that occurs in patients with cystic fibrosis, chronic pancreatitis and other conditions, and Synthroid, which is used in the treatment of hypothyroidism. AbbVie has the rights to sell AndroGel, Creon and Synthroid only in the United States.
Lupron (levprolide acetate), which is also marketed as Lucrin and Lupron Depot, is a product for the palliative treatment of advanced prostate cancer, treatment of endometriosis and central precocious puberty, and for the preoperative treatment of patients with anemia caused by uterine fibroids. Lupron is approved for daily subcutaneous injection and one-month, three-month, four-month and six-month intramuscular injection.
AbbVie's other products include Duopa and Duodopa, Anesthesia products, Dyslipidemia products and Zemplar. AbbVie's levodopa-carbidopa is an intestinal gel for the treatment of Parkinson's disease, which is marketed as Duopa in the United States and as Duodopa outside of the United States. Sevoflurane (sold under the trademarks Ultane and Sevorane) is an anesthesia product that AbbVie sells around the world for human use. AbbVie's dyslipidemia products (TriCor, Trilipix and Niaspan) address a range of metabolic conditions characterized by high cholesterol and/or high triglycerides. Zemplar (paricalcitol) is a product sold around the world for the treatment of secondary hyperparathyroidism associated with stage III, IV and V chronic kidney disease (CKD).
1 N Waukegan Rd
NORTH CHICAGO IL 60064-1802
Company Web Links
- Fitch Affirms Astrazeneca at 'A'; Stable Outlook
- BRIEF-Abbvie announces $5 bln increase to stock repurchase program
- BRIEF-Abbvie sets quarterly cash dividend of $0.64 per share
- Jury clears Abbott and AbbVie in Depakote birth defect trial
- BRIEF-Health Canada grants priority review to Abbvie's investigational regimen of Glecaprevir